SAb Biotherapeutics Email Format
Biotechnology ResearchFlorida, United States51-200 Employees
SAB BIO is a clinical-stage biotechnology company based in Miami, Florida, focused on immunotherapy. It is developing fully human anti-thymocyte immunoglobulin (hIgG) using a novel platform to delay the onset or progression of type 1 diabetes. The company operates within the biotechnology research sector and advances its lead program through clinical development. Its target market includes clinicians and researchers focusing on autoimmune diseases and type 1 diabetes, seeking therapies that can alter disease course. In April 2026 the company announced a multi-year collaboration with Emergent BioSolutions to support the process development and manufacturing of its lead program, SAB-142. The firm, described as mid-sized, participates in industry events and scientific sessions related to autoimmune diabetes to share its progress.